Enovis Corporation (NYSE:ENOV) Receives $47.43 Average Target Price from Analysts

Shares of Enovis Corporation (NYSE:ENOV) have received an average rating of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $47.4286.

Several research firms have recently commented on ENOV. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. BTIG Research raised their target price on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Canaccord Genuity Group decreased their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Evercore reaffirmed an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Finally, Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a research report on Sunday.

Enovis Trading Up 2.2%

Shares of NYSE:ENOV opened at $22.59 on Friday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. Enovis has a 52-week low of $21.00 and a 52-week high of $39.75. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -1.09 and a beta of 1.46. The business has a 50-day moving average price of $23.09 and a 200-day moving average price of $27.33.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. During the same quarter in the prior year, the firm earned $0.98 earnings per share. Enovis’s revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts predict that Enovis will post 2.79 EPS for the current year.

Insider Activity at Enovis

In related news, insider Oliver Engert bought 1,000 shares of the stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the purchase, the insider directly owned 43,640 shares of the company’s stock, valued at $1,112,820. This represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders bought a total of 5,000 shares of company stock valued at $121,983 in the last quarter. 2.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ENOV. Impax Asset Management Group plc raised its position in shares of Enovis by 47.5% during the 3rd quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after purchasing an additional 100,000 shares during the last quarter. Capital Fund Management S.A. acquired a new stake in Enovis in the 2nd quarter worth about $1,682,000. Assenagon Asset Management S.A. acquired a new stake in Enovis in the 3rd quarter worth about $4,045,000. Osaic Holdings Inc. increased its stake in Enovis by 56.0% during the 2nd quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock worth $4,382,000 after buying an additional 50,156 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Enovis by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after buying an additional 125,460 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.